Search research articles
Contact Us
Filters
Showing results (521-530 of 536) with videos related to
Page
of 54
Sort By:
Prostate Cancer and Prostatic Diseases
|
July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer
Bastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Cancers
|
January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
Amina Banda, Bastiaan M Privé, Youssra Allach, et al.
Insect Molecular Biology
|
May 21, 2010
Comprehensive survey of developmental genes in the pea aphid, Acyrthosiphon pisum: frequent lineage-specific duplications and losses of developmental genes
S Shigenobu, R D Bickel, J A Brisson, et al.
Nature Communications
|
October 18, 2022
Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma
Katrin Rabold, Martijn Zoodsma, Inge Grondman, et al.
Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP
|
November 14, 2002
The biotic ligand model: a historical overview
Paul R Paquin, Joseph W Gorsuch, Simon Apte, et al.
BMC Cancer
|
September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
Bastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
The Lancet. Oncology
|
April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
Bastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Trials
|
November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
Bastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2021
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study
Bastiaan M Privé, Steffie M B Peters, Constantijn H J Muselaers, et al.
Eclinicalmedicine
|
February 3, 2021
Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach
M A de Graaf, M L Antoni, M M Ter Kuile, et al.
Page
of 54
Search research articles
Search
Showing results (521-530 of 536) with videos related to
Sort By:
Page
of 54
Prostate Cancer and Prostatic Diseases
|
July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer
Bastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Cancers
|
January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
Amina Banda, Bastiaan M Privé, Youssra Allach, et al.
Insect Molecular Biology
|
May 21, 2010
Comprehensive survey of developmental genes in the pea aphid, Acyrthosiphon pisum: frequent lineage-specific duplications and losses of developmental genes
S Shigenobu, R D Bickel, J A Brisson, et al.
Nature Communications
|
October 18, 2022
Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma
Katrin Rabold, Martijn Zoodsma, Inge Grondman, et al.
Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP
|
November 14, 2002
The biotic ligand model: a historical overview
Paul R Paquin, Joseph W Gorsuch, Simon Apte, et al.
BMC Cancer
|
September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
Bastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
The Lancet. Oncology
|
April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
Bastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Trials
|
November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
Bastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2021
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study
Bastiaan M Privé, Steffie M B Peters, Constantijn H J Muselaers, et al.
Eclinicalmedicine
|
February 3, 2021
Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach
M A de Graaf, M L Antoni, M M Ter Kuile, et al.
Page
of 54